Bristol-Myers Squibb Presents New 4-Year Data from the Long-Term Extensions ... PipelineReview.com (press release) Both patient groups received basiliximab induction, MMF and corticosteroids. Both studies excluded recipients undergoing first transplant with current panel reactive antibodies (PRA, a measure of pre-existing antibodies that may negatively impact the ... |
